Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Embecta Corp. EMBC

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$1.1B
▼ 3.8% YoY
$95.4M
▲ 21.8% YoY
$182.4M
▲ 816.6% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Embecta Corp. markets a portfolio of products for diabetes management, including pen needles, syringes and safety injection devices. It estimates that its products are used by more than 30 million people in over 100 countries for insulin administration and diabetes management. As of September 30, 2025, it had approximately 1,850 regular employees globally, of which approximately 700 were in the United States. It operates three manufacturing sites, located in Ireland, the United States and China. As of September 30, 2025, it held about 655 patents in the United States and various foreign countries, along with about 45 patent applications pending worldwide, protecting its core injection business. On April 1, 2022, Embecta and Becton, Dickinson and Company entered into a Separation and Distribution Agreement. Under that agreement, Becton, Dickinson and Company agreed to spin off its diabetes care business into Embecta as a new, publicly traded company.

Written from the business description in Embecta Corp.'s annual report to the U.S. Securities and Exchange Commission, filed 25 November 2025. Every sentence was checked against that document before publication.

Growth

USD 1.1B
Revenue, FY2025 · full 6-year series below
Revenue $B Net income $B
FY2025 · Revenue 1.1 · Net income 0.1
0.5B1.0B
202020232025
Compound annual growth
−1.5%
−0.1%
−24.7%
−25.9%
−25.3%
−26.4%
+58.7%
+59.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −0.1% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

9 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 22.4% · Net 8.8%
20%40%
202020222025
ROE
FY2021 · ROE 71.1%
20%40%60%
202020222025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: 28%.

Cash & shareholders

USD 35.0M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 182.4
200M400M
202020222025
Net buybacks $M Dividends $M
FY2025 · Dividends 35.0 · Net buybacks ·
15M30M
202020212022202320242025

USD 35.0M in dividends — 37% of the year's profit went back to shareholders.

Total assetsUSD 1.1B
EquityUSD -650.6M
CashUSD 225.5M
Gross debtUSD 1.4B
Net debtUSD 1.2B
Current ratio2.41×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
EMBC, 6-year financial record
Metric 202520242023202220212020
Revenue $B1.11.11.11.11.21.1
Operating income $B0.20.20.20.30.50.5
EBITDA $B0.30.20.30.30.50.5
Income tax $B0.0−0.00.00.00.10.1
Net income $B0.10.10.10.20.40.4
Free cash flow $B0.20.00.00.40.40.5
EPS, diluted $1.621.341.223.897.287.50
Dividend / sh $0.600.600.600.15◌◌
Payout %374449400
ROE %————71.174.7
Shares out B0.060.060.060.06◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 28 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 28 checks were skipped: the balance sheet is not tagged before 2021. 13 checks were skipped: EPS is not tagged before 2020. 13 checks were skipped: revenue is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsSeptember 30
Data on record since2020

Share this section

Download image